Personalized Autoimmune Disease Prevention and Treatment Platform

A comprehensive platform integrating machine learning, precision medicine, and novel therapeutic agents to predict, prevent, and treat autoimmune diseases by selectively targeting pathogenic age-associated B cells.

The original patent focused on treating autoimmune diseases by inhibiting the expansion and function of pathogenic age-associated B cells using nucleic acids encoding human DEF6 and SWAP-70 proteins. However, this approach has limitations, including the need for repeated administrations and potential off-target effects. The new inventive concept addresses these limitations by envisioning a next-generation platform that leverages machine learning, precision medicine, and novel therapeutic agents to provide personalized risk prediction, prevention, and treatment strategies.

The platform consists of four interconnected components: (1) a machine learning model trained on a dataset of pathogenic age-associated B cell markers and clinical outcomes to predict autoimmune disease risk in individual subjects; (2) a therapeutic agent targeting a novel surface receptor specific to pathogenic age-associated B cells, enabling selective elimination of these cells; (3) a composition of small molecule inhibitors of the DEF6 and SWAP-70 proteins, formulated for oral administration to reduce the expansion and function of pathogenic age-associated B cells; and (4) a device for isolating and analyzing pathogenic age-associated B cells from biological samples, utilizing a microfluidic chip with capture sites specific to these cells. The platform also enables the generation of personalized vaccines against autoimmune diseases by isolating and analyzing pathogenic age-associated B cells from individual subjects.

The new inventive concept introduces several novel and non-obvious features, including the integration of machine learning for personalized risk prediction, the use of novel surface receptors for targeted therapy, and the development of a microfluidic device for isolating and analyzing pathogenic age-associated B cells. These features overcome the limitations of the original patent and provide a more comprehensive and effective approach to preventing and treating autoimmune diseases.

Alternative embodiments of the platform could include the use of different machine learning algorithms, the development of novel therapeutic agents targeting other surface receptors, or the integration of additional diagnostic tools, such as genomics or proteomics. Variations of the platform could also focus on specific autoimmune diseases, such as rheumatoid arthritis or multiple sclerosis, or target different stages of disease progression.

The personalized autoimmune disease prevention and treatment platform has significant commercial potential, with applications in the pharmaceutical, biotechnology, and healthcare industries. The platform could be marketed as a comprehensive solution for autoimmune disease management, offering personalized risk prediction, prevention, and treatment strategies to patients and healthcare providers. The market potential is substantial, with an estimated global autoimmune disease market size of over $100 billion by 2025.